June Series - Infectious Disease Testing & Considerations

Home » Events/Calendar » Monthly Webinars » June Series - Infectious Disease Testing & Considerations

June Series - Infectious Disease Testing & Considerations

Throughout this series, we will explore various aspects surrounding eligibility in consideration of screening and evaluation of infectious disease and RCDADs. We will discuss the process of Nucleic Acid Testing, Serology Testing, Microbiological Evaluation and current trends in epidemics and infectious diseases.

User instructions: Hover over the speaker's image to reveal his or her biography. If using a mobile device, tap the speaker's image to reveal his or her biography.

Presentation 1

Presentation Summary:

This session will review and summarize trends in infectious and RCDAD testing and screening practices. We will also review the challenges which arise in essential testing procedures like NAT, serology and more. As we discuss the challenges, we will also review the impact that poor or insufficient samples may have on the outcome of such tests, and finally, we will elaborate upon the method of reading and interpreting these tests and reports.

Learning Objectives:

  1. What are some different types of serology testing methodologies?
  2. What is a “window period” with an infectious disease?
  3. How do initially-reactive results affect testing algorithms?
  4. How does poor sample quality affect testing and results?
  5. What can the lab and the client do to minimize poor sample quality?
  6. What challenges does the testing lab have to overcome?
  7. How do you interpret a serology screening report?

Rod Hale

Rod Hale

Rod Hale, Director of Laboratory Operations at VRL-Eurofins, graduated magna cum laude from Utah State University in 1992 with a Bachelor’s of Science in Applied Biology. In 1997, he earned his Masters of Science in Medical and Molecular Genetics from Indiana University. He has 20 years’ experience in the Human Cell & Tissue Product (HCT/P) industry. The first 12 years were spent at Laboratories At Bonfils, (which became LABS, Inc.). Rod performed various immunological and molecular tests for the screening of eye, tissue, organ and other transplant donors, eventually becoming the manager of the Infectious Disease department, where he successfully implemented and oversaw the testing logistics that enabled the small regional lab to achieve nationwide growth. In 2010, he helped establish the human-screening division of VRL, which has since become the leader in HCT/P screening.

NAT & Serology Testing & Challenges

Speaker: Rod Hale, MS
Day: June 6, 2018
Time: 2:00 p.m. - 3:00 p.m. EST

Presentation 2

Presentation Summary:

Through this session we will cover all aspects of HCT/P microbiology at a basic to intermediate level. We will review traditional ID or rapid ID such as MALDI-TOF and sequencing, and why environmental monitoring plays a role in this and many more essential details in this aspect of eligibility evaluation.

Learning Objectives:

  1. Outline the basic concept of microbiological testing and evaluation.
  2. Define why method suitability is important.
  3. Identify good and not so good microorganism identifications.
  4. Outline the basics of a log reduction study.
  5. Define expectation of bioburden reduction studies.

Carolyn Jacobs

Carolyn Jacobs

Carolyn has a held a wide range of positions within the laboratory and microbiological arenas, and has over 40 years of dedicated experience in this field. Carolyn has served as a microbiological consultant to multiple renowned laboratories, including LABS, Inc. and VRL Laboratories. Carolyn now owns the firm GMP by CynJay, LLC, a consulting firm which advises multiple eye banks, tissue banks, medical device and biological manufacturers.

In addition to her extensive advisory roles, Carolyn has served as a Senior Scientist & Director of Microbiology at LABS, Inc., Chief Microbiologist/Microbiology Manager at Gambro, Blood Component Technology, and the Production Manager at PASCO Laboratories, a Division of Becton Dickinson. Carolyn holds a bachelor’s degree in microbiology from Colorado State University, and is Regulatory Affairs Certified.

Microbiology 101 of HCT/Ps - Bioburden, Sterility, Environmental Monitoring and the Kitchen Sink

Speaker: Carolyn Jacobs
Date: June 13, 2018
Time: 2:00 p.m. - 3:00 p.m. EST

Presentation 3

Presentation Summary:

Through this session we will review and evaluate current and emerging infectious disease, epidemics and endemic areas.

Learning Objectives:

  1. Outline current emerging and infectious diseases.
  2. Identify various areas indicative of increased risk.
  3. Outline various trends in epidemics and endemic areas.

Dr. Imrit-Thomas

Dr. Imrit-Thomas

Dr. Thomas is the Associate Medical Director at LifeNet Health and an Associate Professor of Medicine at EVMS. She is board certified in internal medicine and infectious disease. Dr. Thomas earned her undergraduate degree at Arts Queens College, City University of New York. She completed her fellowship at the University of Medicine & Dentistry of New Jersey, Sub-Internship at Memorial Sloan Kettering Cancer Center and her Clerkship at Harvard School of Medicine. Prior to her role at LifeNet Health, Dr. Thomas was an Infectious Disease Attending for multiple hospitals including Sentara Medical Group, Hamptons VA, and more.

Emerging Infectious Disease

 

Speaker: Dr. Kavita Imrit-Thomas
Date: June 20, 2018
Time: 2:00 p.m. - 3:00 p.m. EST